Literature DB >> 5118683

Development of resistance to daunomycin (NSC-82151) in Ehrlich ascites tumor.

K Dano.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1971        PMID： 5118683

Source DB:  PubMed          Journal:  Cancer Chemother Rep        ISSN： 0069-0112


× No keyword cloud information.
  18 in total

1.  Antitumor activity of the two epipodophyllotoxin derivatives VP-16 and VM-26 in preclinical systems: a comparison of in vitro and in vivo drug evaluation.

Authors:  P B Jensen; H Roed; T Skovsgaard; E Friche; L Vindeløv; H H Hansen; M Spang-Thomsen
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

2.  A phase II study of intensive-dose epirubicin/verapamil as induction therapy followed by intensive-dose ifosfamide for advanced breast cancer.

Authors:  T Langenbuch; K Mross; W Jonat; D K Hossfeld
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

3.  In vitro cellular characteristics and survival responses of human astrocytoma clones to chloroethyl-nitrosoureas and dianhydrogalactitol.

Authors:  N H Rubin; C Casartelli; B G Macik; W R Boerwinkle; S C Barranco
Journal:  Invest New Drugs       Date:  1983       Impact factor: 3.850

4.  In vitro and in vivo study of cross resistance between daunorubicin and daunorubicin-DNA complex in Ehrlich ascites tumor.

Authors:  T Skovsgaard
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

Review 5.  Tumour cell resistance to anthracyclines--a review.

Authors:  S Kaye; S Merry
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

6.  Contribution of drug transport and reductases to daunorubicin resistance in human myelocytic cells.

Authors:  G Vasanthakumar; N K Ahmed
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

7.  Heterogeneous responses of an in vitro model of human stomach cancer to anticancer drugs.

Authors:  S C Barranco; C M Townsend; M A Quraishi; N L Burger; H C Nevill; K H Howell; W R Boerwinkle
Journal:  Invest New Drugs       Date:  1983       Impact factor: 3.850

8.  Effect of verapamil on daunorubicin accumulation in Ehrlich ascites tumor cells.

Authors:  E Friche; T Skovsgaard; N I Nissen
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

9.  In vivo inhibition of etoposide-mediated apoptosis, toxicity, and antitumor effect by the topoisomerase II-uncoupling anthracycline aclarubicin.

Authors:  B Holm; P B Jensen; M Sehested; H H Hansen
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

10.  Detection of induced resistance in short-term-tests. Adriamycin-resistant sarcoma 180.

Authors:  M Volm; C Lindner
Journal:  Z Krebsforsch Klin Onkol Cancer Res Clin Oncol       Date:  1978-01-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.